Branca Bunús
Branca Bunús is an Irish gene therapy company that develops and sells BrPERfect® HPAE polymer-based transfection reagents to CDMOs, biotech, and pharma customers for viral vector and protein production workflows, with a strategic China channel via Duoning Biotech.
- Company typePrivate
- Founded2019
- HeadquartersDublin, Ireland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Branca Bunús does
Branca Bunús Ltd is a private Irish gene therapy company founded in 2019 and headquartered in Cherrywood Business Park, Loughlinstown, Co. Dublin. The company develops and commercializes HPAE (High-Performance Aqueous-phase Electrostatic) polymer-based non-viral gene delivery vectors and transfection reagents under its lead BrPERfect® product line. Its reagents are positioned for viral vector transient production in cell and gene therapy manufacturing, protein transient production workflows, and the targeted delivery of pDNA, siRNA, mRNA, and CRISPR complexes in vitro and in vivo.
The company's core technology is its HPAE platform, a proprietary polymer chemistry designed to deliver higher transfection efficiency and cell viability than traditional reagents while remaining cost-competitive and scalable from academic bench scale to CDMO production scale. Branca Bunús monetizes through direct B2B enterprise sales of BrPERfect® reagents and custom formulations to contract development and manufacturing organizations (CDMOs), biotechnology companies, and pharmaceutical companies, with quote-based pricing and dedicated technical support. Academic research labs are a secondary segment.
The company operates with a small team (1–10 employees) led by founder Prof. Wenxin Wang (UCD) and CEO/Managing Director Dr. Hongyun Tai. It has secured FDA Type II Drug Master File acceptance (DMF #39924, June 2024), ISO 9001:2015 certification from NSAI, and the 2025 NovaUCD Innovation Award. Its primary international growth lever is a strategic partnership with Duoning Biotech (announced November 2024) for co-development and commercialization of BrPERfect® reagents targeting biopharmaceutical customers in China and beyond, with active Irish government support via Enterprise Ireland.
Branca Bunús firmographics
Firmographics- Name
- Branca Bunús
- Legal name
- Branca Bunús Ltd
- Website
- https://brancabunus.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Branca Bunús is an Irish gene therapy company that develops and sells BrPERfect® HPAE polymer-based transfection reagents to CDMOs, biotech, and pharma customers for viral vector and protein production workflows, with a strategic China channel via Duoning Biotech.
- Ownership category
- akta.pro rank
Branca Bunús industry classification
Industry- Product category
- Transfection Reagents
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)
- akta.pro secondary industries
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)
Keywords
Where Branca Bunús is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices1 record
Markets served
Branca Bunús business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Transfection Reagent Sales: Sale of high-performance transfection reagents (BrPERfect® series) to researchers, CDMOs, biotech companies, and pharmaceutical companies. Products include reagents for viral vector transient production and protein transient production workflows. Premium quality at competitive prices with scalability from small academic labs to large-scale CDMO production.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing for enterprise and research customers |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Branca Bunús product offering
Product offeringCore offering
Branca Bunús develops and commercializes the BrPERfect® Series of HPAE polymer-based non-viral transfection reagents used for delivery of pDNA, siRNA, mRNA, and CRISPR complexes in cell and gene therapy manufacturing and protein transient production. The reagents are sold to CDMOs, biotech firms, and pharmaceutical companies, with custom formulations available for specific delivery requirements.
Product overview
Branca Bunús is a gene therapy company offering a unified product portfolio centered on its HPAE polymer-based transfection reagent platform. The core product is the BrPERfect® Series of next-generation transfection reagents, which enables researchers, CDMOs, and biotech/pharma companies to achieve high-efficiency, scalable, and cost-effective delivery of pDNA, siRNA, mRNA, and CRISPR complexes for gene therapy and protein production applications. The company also provides custom solutions tailored to specific delivery requirements.
Differentiator
Problem solved
Functional benefit
Brands
- BrPERfect®: HPAE polymer-based transfection reagent series for gene delivery in cell and gene therapy, and protein transient production workflows.
Products and services
- BrPERfect® Series Transfection Reagents High-performance HPAE polymer-based transfection reagents for non-viral delivery of pDNA, siRNA, mRNA, and CRISPR complexes in vitro and in vivo. Used by CDMOs, biotech companies, pharmaceutical companies, and academic research labs for viral vector transient production in cell and gene therapy and for protein transient production workflows.
Quantifiable outcome
- Higher transfection efficiency and cell viability than traditional transfection reagents
- +2 more outcomes
Companies that use Branca Bunús
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Branca Bunús technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Branca Bunús partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Duoning BiotechcoreStrategic partnership for co-development and commercialization of BrPERfect® next-generation transfection reagents. Focuses on providing innovative, high-performance gene delivery solutions for biopharmaceutical companies in China and beyond. Partnership celebrated during Irish ministerial visit to Shanghai in March 2025 with Irish government delegation including Minister for Housing James Browne TD, Irish Ambassador to China Dr Nicholas O'Brien, and Enterprise Ireland representatives.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Branca Bunús competitors and assessment
Company assessmentDirect peers
- Polyplus (Sartorius): Polyplus, acquired by Sartorius in 2023, is the leading provider of PEI-based transfection reagents (PEIpro, FectoPRO) used in viral vector and protein production at CDMO scale. It is the closest direct competitor to Branca Bunús's BrPERfect polymer-based reagents serving the same gene therapy and bioprocessing customers.
- Mirus Bio: Mirus Bio, now part of Roche, manufactures the TransIT series of transfection reagents widely used in viral vector and protein production. Its broad reagent portfolio for plasmid, siRNA, mRNA, and CRISPR delivery directly competes with Branca Bunús's multi-modality BrPERfect platform.
- MaxCyte: MaxCyte specializes in electroporation-based transfection systems for cell engineering, including viral vector and cell therapy manufacturing. It is a specialist comparable focused on high-efficiency delivery for gene therapy production workflows.
Broad incumbents
- Cytiva (formerly GE Life Sciences): Cytiva is a major bioprocessing tools provider with a transfection reagent line serving CDMOs and biopharma manufacturers. It serves overlapping customers with broader upstream/downstream bioprocessing offerings rather than specializing in delivery chemistry.
- Lonza Bioscience: Lonza is a leading global CDMO and supplier of cell-line engineering and transfection technologies, including its proprietary transient expression systems. It competes indirectly through its end-to-end bioprocess offerings that include transfection as one component.
- Thermo Fisher Scientific (Gibco): Thermo Fisher, through its Gibco brand, offers lipid-based transfection reagents (e.g., Lipofectamine) that dominate the research and emerging bioprocessing market. It is a broad incumbent with a much larger sales channel and broader catalog than Branca Bunús.
- Bio-Rad Laboratories: Bio-Rad offers transfection reagents such as the TransFectin line and provides life science research tools widely used in gene delivery applications. It is a broad incumbent serving overlapping customers across research and bioprocessing.
Emerging players
- OZ Biosciences: OZ Biosciences is a smaller specialty supplier of transfection reagents (lipid and polymer based) targeting viral vector production and gene delivery. It competes in the same niche with a more limited portfolio than Branca Bunús.
- Polysciences: Polysciences manufactures specialty transfection reagents including PEI-based products used in transient protein and viral vector production. It is an emerging niche player with overlapping polymer transfection technology serving similar CDMO accounts.
Others
- Akron Bio (Akron Biotechnology): Akron Bio supplies ancillary reagents and raw materials for cell and gene therapy manufacturing. It serves the same CDMO/biopharma customers with adjacent (rather than competing) reagent products, making it a comparator for go-to-market and customer relationships in the gene therapy supply chain.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Branca Bunús compliance and trust
Trust signalCompliance2 records
Branca Bunús financial estimates
Financial estimateRevenue estimate
Valuation estimate
Branca Bunús leadership team
Management profileNumber of profiles
Profiles2 records
Branca Bunús funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Branca Bunús M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Branca Bunús
What does Branca Bunús do?
Branca Bunús develops and commercializes the BrPERfect® Series of HPAE polymer-based non-viral transfection reagents used for delivery of pDNA, siRNA, mRNA, and CRISPR complexes in cell and gene therapy manufacturing and protein transient production. The reagents are sold to CDMOs, biotech firms, and pharmaceutical companies, with custom formulations available for specific delivery requirements.
Is Branca Bunús a public or private company?
Branca Bunús is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Branca Bunús founded?
Branca Bunús was founded in 2019. It employs 1 to 10 people.
Where is Branca Bunús based?
Branca Bunús is headquartered in Dublin, Ireland, in the Europe region.
How does Branca Bunús make money?
One revenue line is on record: transfection Reagent Sales.
Who are Branca Bunús's main competitors?
Direct peers on record are Polyplus (Sartorius), Mirus Bio and MaxCyte. Broad incumbents are Cytiva (formerly GE Life Sciences), Lonza Bioscience, Thermo Fisher Scientific (Gibco) and Bio-Rad Laboratories. Emerging players are OZ Biosciences and Polysciences. Akron Bio (Akron Biotechnology) is listed as an others.
Does Branca Bunús have an API?
No public API is recorded for Branca Bunús.
What industry is Branca Bunús in?
Branca Bunús's product category is Transfection Reagents. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 325414 and its SIC code is 2836.